Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Meet the Leaders (38)
November 22, 2004
- Shionogi: Profits Up Sharply Despite Decline in Sales
November 15, 2004
- Korosho Withdraws Recommendations for Antibiotics Skin Tests: Safety Info
November 15, 2004
- Santen: Sales Down 2.3% to \45.0 Bil.
November 15, 2004
- Chugai Ready to Supply Tamiflu for 15 Mil. Patients
November 15, 2004
- Expecting New Products to Spark Recovery: Mr Morita of Daiichi
November 15, 2004
- REGULATORY NEWS IN BRIEF
November 15, 2004
- Tanabe to Focus on Remicade in Near-term Strategy: Mr Hayama
November 15, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
November 15, 2004
- Dainippon: Declines in Sales, Profits due to NHI Price Reduction
November 15, 2004
- The 5th Kitasato University-Harvard School of Public Health Symposium
November 15, 2004
- Torii: Sales Up 1.5% to \21.9 Bil.
November 15, 2004
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
November 15, 2004
- Teijin: Med., Pharm Business Sales Up 3.2% to \47.4 Bil.
November 15, 2004
- Monitor
November 15, 2004
- Gene Chip Accounts for 65% of Affymetrix Japan's Sales
November 15, 2004
- DIAGNOSTIC NEWS IN BRIEF
November 15, 2004
- PhRMA Publishes Japanese Version of Principles for Conducting Clinical Trials
November 15, 2004
- OTC NEWS IN BRIEF
November 15, 2004
- Mediceo HD Forms Capital Tie-up with Chain Management
November 15, 2004
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…